News

GlobalData on MSN4d
EC approves AstraZeneca’s Calquence combo to treat MCL
The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib), ...
AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer
AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting ...
PharmTech2d
EU Approves AstraZeneca Mantle Cell Lymphoma Treatment
Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...
Medical Dialogues4d
AstraZeneca Calquence plus chemoimmunotherapy approved in EU for 1st-line mantle cell lymphoma
Cambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been ...
PMLive5d
AstraZeneca’s Calquence approved by EC for first-line mantle cell lymphoma use
AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved ...
AstraZeneca's Calquence gets EU approval to treat adults with MCL
(Alliance News) - AstraZeneca PLC on Tuesday said Calquence plus chemoimmunotherapy has been approved in the European Union for previously untreated mantle cell lymphoma in adults.
The Pharma Letter5d
Calquence plus chemoimmunotherapy approved in the EU
UK pharma major AstraZeneca (LSE: AZN) today revealed that its Calquence (acalabrutinib) in combination with bendamustine and ...